Conversation with The Cancer Letter Free

Sharpless: “I am now looking at the entire portfolio—focusing on areas where NCI is an essential player”

A year after starting his job as NCI director, Ned Sharpless is reviewing the entire spectrum of NCI research in an effort to focus on areas where the institute plays a key role.

Sharpless: “I am now looking at the entire portfolio—focusing on areas where NCI is an essential player”

So, you'd like a cancer center designation… Sharpless offers advice on what makes a center in the era of
“outreach and engagement”

Here are the strings attached to the NIH funding increase: House and Senate report language

Caligiuri, Califano, Gottlieb among new members of National Academy of Medicine

In Brief

Count Me In pioneers new model in patient-partnered research

Roswell Park gets over $6M in Moonshot funds to lead immuno-oncology data management resource

MSK's Michel Sadelain wins Pasteur-Weizmann/Servier Prize

Biden, Charpentier, Doudna, Eng, and Thun win ACS Medal of Honor

Chartbook illustrates inequities in cancer prevention, treatment and survivorship

NIH memorial service for Alan Rabson scheduled for Oct. 30

Clinical Roundup

Keytruda-Inlyta combination improved OS and PFS in front line for advanced, metastatic RCC

Skin creams safe to use before radiation therapy

Automated system identifies dense tissue in mammograms

150-year-old drug might improve radiation therapy

Drugs & Targets

Myriad's test receives FDA approval as companion diagnostic for Pfizer's Talzenna

FDA publishes guidance on MRD as a biomarker

Huge variations between countries in time for reimbursement decisions on new cancer drugs

AbbVie's sNDA accepted for priority review for Imbruvica in combination with Gazyva for previously untreated CLL

The Parker Institute, Xyphos Biosciences developing universal programmable CAR-T cells

PanTher Therapeutics, MD Anderson collaborate on pancreatic cancer treatment

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login